Correction to: Nature Biotechnology https://doi.org/10.1038/s41587-020-0487-2, published online 7 April 2020.
In the version of this article initially published, Jürgen Kuball was quoted as saying that monoclonal antibody and CAR-T cell therapies rely “on the clonal nature of a certain T cell receptor.” This should have read “on the clonal nature of a certain receptor.” The article also said that γδ T cells are almost entirely CD8+; this characterization has been deleted. Finally, the phrase “only cells with intact receptors retain antitumor activity” was linked to https://cancerimmunolres.aacrjournals.org/content/early/2020/02/04/2326-6066.CIR-19-0513.long; the link has been changed to https://doi.org/10.1182/blood-2012-05-432427. The errors have been corrected in the HTML and PDF versions of the article.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Garber, K. Publisher Correction: γδ T cells bring unconventional cancer-targeting to the clinic — again. Nat Biotechnol 38, 649 (2020). https://doi.org/10.1038/s41587-020-0526-z
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41587-020-0526-z